Skip to content
Screener

Ginkgo Bioworks DNA Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue$33.0MMiss by $4.1M
EPS-$1.42Beat by $0.38
Revenue estimate$37.1M
EPS estimate-$1.80

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$21.6M
EPS estimate-$0.58

Financials

Q4 2025

Income statement

See full
Revenue$33.4M-23.8%
Operating income-$70.8M+31.7%
Net income-$80.8M+24.9%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$212.4M-64.9%
Total debt$439.9M-6.0%
Total equity$508.6M-29.0%
Total assets$1.1B-18.7%

Cash flow

See full
Operating cash flow-$47.7M-12.4%
CapEx$5.0K-100.0%
Free cash flow-$47.7M+15.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$503.5M-10.8%
Enterprise value$731.02M+71.4%
P/S3.4×+0.9×

Profitability

See full
Operating margin-200.5%-31.6pp
Net margin-209.1%-24.4pp
FCF margin-119.5%-26.9pp

Returns & leverage

See full
Return on equity-51.1%-6.8pp
Debt / equity0.9×+0.2×
Current ratio4.9×-0.7×

FAQ

When did Ginkgo Bioworks report Q4 2025 earnings?
Ginkgo Bioworks (DNA) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Ginkgo Bioworks's Q4 2025 revenue and EPS?
Ginkgo Bioworks reported revenue of $33.0M and eps of $-1.42 for Q4 2025.
Did Ginkgo Bioworks beat estimates in Q4 2025?
Revenue missed the consensus estimate of $37.1M by $4.1M. EPS beat the consensus estimate of $-1.80 by $0.38.
How did Ginkgo Bioworks's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 24.7% from $43.8M a year earlier and eps grew 22.0% from $-1.82.
Where can I find Ginkgo Bioworks's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-012339) and the 10-K periodic report (0001628280-26-012346) directly on SEC EDGAR. The filing index links above go to sec.gov.